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One Sentence Summary:  This paper develops a novel machine learning methodology 
(ToPs – Trees of Predictors) that discovers clusters of patients and creates cluster-specific 
predictive models of survival for patients in those clusters, and then applies the 
methodology to the United Network for Organ Sharing data set to demonstrate 
significantly improved personalized predictions of survival in patients with advanced 
heart failure before and after heart transplantation. 
 
Abstract: Given the limited pool of donor organs, accurate predictions of survival on the 
wait list and post-transplantation are crucial for cardiac transplantation decisions and 
policy.  However, current clinical risk scores do not yield accurate predictions. We 
develop a new methodology (ToPs – Trees of Predictors) built on the principle that 
specific predictors should be used for specific clusters within the target population.  ToPs 
discovers these specific clusters of patients and the specific predictor that perform best 
for each cluster. In comparison with current clinical risk scoring systems, our method 
provides significant improvements in the prediction of survival time on the wait list and 
post-transplantation.  For example: in terms of 3-month survival for patients who were on 
the US patient wait-list in the period 1985-2015, our method achieves AUC of 0.847; the 
best commonly used clinical risk score (MAGGIC) achieves 0.630. In terms of 3-month 
survival/mortality predictions (in comparison to MAGGIC), holding specificity 
at 80.0%, our algorithm correctly predicts survival for 1,228 (26.0%) more patients out of 
4,723 who actually survived; holding sensitivity at 80.0%, our algorithm correctly 
predicts mortality for 839 (33.0%) more patients out of 2,542 who did not survive. Our 
method achieves similar improvements for other time horizons and for predictions post-
transplantation.  Therefore, we offer a more accurate, personalized approach to survival 
analysis that can benefit patients, clinicians and policymakers in making clinical 
decisions and setting clinical policy. Because risk prediction is widely used in diagnostic 
and prognostic clinical decision-making across diseases and clinical specialties, the 
implications of our methods are far-reaching. 
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INTRODUCTION 
 
Heart transplantation is the treatment of last resort for patients suffering from end-stage 
heart failure (1-3). For such patients, a transplant represents the opportunity for improved 
life expectancy and quality of life.  However, the demand for hearts (the number of 
patients on the wait-list) exceeds the supply (the number of donors) so that patients 
(potential recipients) are at substantial risk of dying while on the waiting list.  In the U.S. 
between 1985 and 2015, more than 36,000 patients were on a waiting list for a heart 
transplant without obtaining one; of these, more than 15,000 (41.6%) died within a year 
of entering the wait list (4-6). In the same period, more than 60,000 patients received a 
heart transplant; of these, more than 8,000 (13.3%) patients died within one year.   
 
Minimizing mortality on the wait list and maximizing survival after transplant are 
difficult problems (7-15) but are crucial for effective transplantation practice and policy 
(16, 17).  Dealing effectively with these problems requires accurate predictions of 
survival for patients on the wait list and for patients who receive transplants.  However, 
the clinical risk scores that are currently used to predict survival on the wait list and 
survival after transplantation perform rather poorly: for survival on the wait list, none of 
them achieves AUC (Area Under the receiver operating characteristic Curve) of 0.650 at 
time horizons of 3 months, 1 year, 3 years or 10 years; for survival post-transplantation, 
none of them achieves AUC of 0.600 for the same time horizons.  This poor performance 
results (at least in part) from the inability of the current clinical methods to properly 
address three complex aspects: 
 The populations of patients and donors are extremely heterogeneous and the 
effect of particular features (covariates) on survival is different for different 
subpopulations. 
 The dependence of survival on features involves the interactions between features 
– in particular, dependence is non-linear – and the interactions are different for 
different subpopulations.  
 The features and interactions between features that have the most effect on 
survival depend on the time horizon: the features and interactions between 
features that are most important for survival for 1 year are different from those 
that are most important for survival for 3 months or 3 years or 10 years.   
Current clinical risk scores fail to address any of these complex aspects.  They ignore the 
heterogeneity of the populations and employ a one-size-fits-all methodology.  They 
ignore potential interactions between features and compute a risk score that is linear in 
scores associated to individual features.  They ignore the differences between time 
horizons, computing only a single risk score. 
 
Our work develops and applies novel machine learning methods for survival 
analysis to craft a methodology, Trees of Predictors (ToPs), and a particular 
implementation, ToPs/Regression (ToPs/R), that is expressly designed to address all these 
complex aspects. We address the heterogeneity of the patient and donor populations by 
endogenously identifying specific subpopulations (clusters) and applying different 
predictors to different subpopulations. We address the interactions between features by 
constructing non-linear predictors for some subpopulations and address the different 
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importance of features for different subpopulations by choosing different coefficients in 
the predictors constructed for those subpopulations.  We address the importance of 
different features and different interactions between features at different time horizons by 
tuning the construction to the particular time horizon.  Our method is interpretable and 
applies to survival both on the wait list and post-transplantation – and so provides an end-
to-end methodology for use by clinicians. Our underlying construction may be carried out 
entirely offline, allowing the calculations for a particular patient to be carried out in real-
time.   Our website provides a convenient clinical decision support system that is readily 
usable in clinical settings: http://medianetlab.ee.ucla.edu/ToPs_TransplantSurvival. Our 
method yields significantly more accurate predictions than current clinical methods (and 
more accurate predictions than alternative machine learning methods that are not tailored 
for the particular application) for both survival on the wait-list and survival post-
transplantation, and for all considered time horizons. 
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RESULTS 
Performance improvement of ToPs/R 
Tables 1 and 2 show the prediction performance in wait-list and post-transplantation for 
our method (ToPs/R), current clinical risk scores, familiar regression models and several 
machine learning benchmarks. (We conducted our study using the United Network for 
Organ Sharing database of patients who were registered to undergo heart transplantation 
during the years from 1985 to 2015; see Methods and Methodology for a more complete 
description of the data.) As can be seen, our method provides very large improvements in 
the prediction of survival time on the wait list and post-transplantation in comparison 
with the clinical risk scores. Furthermore, our method also shows consistently and 
statistically significantly (p-value < 0.01) better performance than the machine learning 
benchmarks.  For instance, for wait-list survival at a time horizon of 3 months, our 
method achieves Area Under the receiver operating characteristic Curve (AUC) of 0.847 
(95% Confidence Interval (CI): 0.846-0.848).  By contrast, the best performing currently 
used clinical predictor achieves AUC of only 0.630 (CI: 0.629-0.632). The improvements 
achieved by our algorithm are similar both for other time horizons and for post-
transplantation predictions. 
 
Absolute increase (or percentage increase) in AUC is a measure of improved 
performance, but understates the performance improvement.  A predictor performs well if 
the region under the Receiver Operating Characteristic (ROC) curve is large; or 
equivalently if the area above the ROC curve is small.  AUC measures the area of the 
region under the ROC curve, but a more revealing measure of performance improvement 
is in terms of predictive loss – the area of the region above the ROC curve; this is just the 
difference 1-AUC. We therefore express performance gain of our method over a 
competing method as the reduction in the predictive loss expressed as a percentage.  As 
Table 3 demonstrates, for survival in the wait list ToPs/R out-performs the best clinical 
risk scores by 35.2-58.6%, the basic regression methods (on which ToPs/R is built) by 
18.6-36.3%, and the best machine learning benchmarks by 5.5-12.8% at all time horizons; 
for survival post-transplantation, the improvements are smaller but still very substantial.  
All the improvements are statistically significant (p-value < 0.01). 
 
 Figures 1(a) and 1(b) provide visual evidence of the extent of the improvement of our 
method over competing methods.  Figure 1(a) shows the actual ROC curves for ToPs/R, 
for the best machine learning algorithm (Random Forest), and for the best clinical risk 
score (Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC)) for 3-month 
survival on the wait list; Figure 1(b) shows the actual ROC curves for 3-month survival 
post-transplantation (18).   
 
An alternative illustration of the improvement achieved by our method is the 
increase in the number of correct predictions.  For 3-month survival in the wait list, 
holding specificity at 80.0%, ToPs/R correctly predicted survival for 1,228 more patients 
(26.0% of the 4,723 patients survived up to 3 months) and, holding sensitivity at 80%, 
ToPs/R correctly predicted mortality for 839 more patients (33.0% of the 2,542 patients 
who died within 3 months), in comparison with the best clinical risk score, MAGGIC. 
For 3 month survival post-transplantation, with the same specificity and sensitivity, 
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ToPs/R correctly predicted survival for 1,401 more patients (13.0% of the 10,777 patients 
who survived up to 3 months), and correctly predicted mortality for 158 more patients 
(14.0% of 1,129 patients who died within 3 months), in comparison with the best clinical 
risk score (the Index for Mortality Prediction After Cardiac Transplantation (IMPACT)) 
(19).  Because survival (or mortality) in the wait list (urgency) and survival post-
transplantation (benefit) are perhaps the most important factors in transplant policy, these 
predictive improvements are of great importance. 
 
Predictive features  
Some features are more predictive of survival than other features, and some features are 
more predictive for survival for a particular time horizon than for other time horizons.  
Figure 2 presents heat maps displaying the predictive value of the features for various 
predictions over different time horizons.  For instance, as can be seen in Figure 2(f), 
donor's age is a very predictive feature for long-term post-transplantation survival, but it 
is less predictive of short-term survival; the most predictive features for short-term 
survival are the need for advanced cardiac and respiratory life support (ECMO and 
ventilator support, etc.). Moreover, the predictive power of donor's age also differs across 
various subpopulations as well as across different time horizons. For instance, as Figure 3 
shows, ToPs/R splits the entire population according to whether the creatinine level is 
below/above 4.64 mg/dL.  The set of patients for whom the creatinine level is above 4.64 
mg/dL is deemed Cluster 17; ToPs/R does not split this cluster any further.  To see the 
importance of features in Cluster 17, refer again to the heat map Figure 2(d): we see that 
comorbidities such as diabetes are much more predictive of long-term survival than the 
donor's age. This is consistent with the fact that chronic kidney disease and its 
interrelated set of comorbidities (which includes diabetes) can generally worsen 
cardiovascular outcomes (20-21). Diabetes does not have the same predictive power for 
other groups of patients.  For example, in Cluster 5 (patients with creatinine level below 
1.74 mg/dL, Panel Reactive Antibody (PRA) above 27% and BMI within the "normal" 
range 23.0-27.3 kg/m, the donor's age and the ischemic time have more predictive power 
than diabetes. In this particular example, creatinine serves as a discriminative feature that 
filters out populations for whom survival prediction needs to consider different predictive 
features via "customized" predictive models. This example also sheds light on how 
ToPs/R can recognize the impact of comorbidities – in this case renal failure and diabetes 
– on a patient's survival: ToPs/R recognizes some features related to comorbidities as 
being discriminative, and also learns the appropriate predictive features for patients with 
those comorbidities. (Note that two of the clinical risk scores – Donor Risk Index (DRI) 
and IMPACT – do not use diabetes as an input to their prediction rule; this may lead to 
misinformed surgical decisions for patients with comorbidities (19, 22).) 
 
LVADs 
Figure 4(a) shows the survival curves (using Kaplan-Meier estimators) for patients who 
received an LVAD (left ventricular assist device) in the periods 2005-2009 and 2010-
2015, the survival curves for patients who had similar features (determined by Propensity 
Score Matching (23)) – referred to as “LVAD-eligible” – but who did not receive an 
LVAD in the same periods, and the survival curves for the overall population in the same 
periods.  For patients who received an LVAD in the period 2005-2009, survival 
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probabilities at 3 months, 1 year and 3 years are approximately 0.896, 0.777, 0.626 
(respectively); for patients who received an LVAD in the period 2010-2015, survival 
probabilities at the same time horizons are approximately 0.931, 0.831, 0.640 
(respectively).  (Because most patients who received an LVAD did so after 2005, there is 
not enough data for meaningful analysis of 10-year survival.) In comparison with LVAD-
eligible patients, those who actually received an LVAD experienced much superior 
survival probabilities at all time horizons.  In terms of predictions of survival of LVAD 
patients on the wait-list, ToPs/R yields AUC of 0.826, 0.821, 0.796 at time horizons of 3-
months, 1-year, 3-years. This performance is similar to the performance of ToPs/R for the 
population as a whole and superior to all the clinical risk scores and machine learning 
benchmarks.  
 
Figure 4(b) shows the survival curves for post-transplantation patients who received an 
LVAD in the periods 2005-2009 and 2010-2015, the survival curves for post-
transplantation “LVAD-eligible” patients in the same periods, and the survival curves for 
the overall population of post-transplantation patients in the same periods.  As can be 
seen, survival post-transplantation is not very different for the various groups of patients.  
But when we compare Figures 4(a) and 4(b), it can also be seen that survival is much 
better for patients who received a heart transplant (survival probabilities at 3 months, 1 
year and 3 years are approximately 0.926, 0.881, 0.808, respectively) than for patients 
who were maintained on LVAD (survival probabilities at the same time horizons are 
approximately 0.931, 0.831, 0.640, respectively).   
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DISCUSSION 
 
In this study, we develop a methodology for personalized prediction of survival for 
patients with advanced heart failure while on the wait-list and after heart transplantation. 
Our methods and associated findings are important because they outperform the clinical 
risk scores currently in use and also because they automate the discovery and application 
of cluster-specific predictive models and tune predictions to the specific patient for which 
the prediction is to be made. The clinical and public health implications of our findings 
are broad and include improved personalization of clinical assessments, optimization of 
decision making to allocate limited life-saving resources and potential for healthcare cost 
reduction across a range of clinical problems.  
 
Key Findings 
We emphasize three key findings of our study: 
 Our method significantly outperforms existing clinical risk scores, familiar 
regressions and state-of-the-art machine learning benchmarks in terms of accurate 
prediction of survival on the wait-list and post-transplantation. 
 This improvement in performance has clinical significance: our method correctly 
predicts both survival and mortality for a larger number of patients. 
 There is substantial heterogeneity – both across clusters of patients and across 
different time horizons.  Our method captures this heterogeneity far better than 
other methods. 
 
Performance improvement of ToPs/R 
As the results show, ToPs/R achieves large performance improvements over current 
clinical risk-scoring models.  It does so by explicitly addressing the weaknesses of these 
clinical models: 
 Tops/R addresses the heterogeneity of the population(s) by identifying 
subpopulations (clusters) and the specific predictors that are best suited to 
prediction in each subpopulation.  Tops/R makes predictions that are personalized 
to the features of the patient (or patient and donor). 
 Tops/R addresses the interactions between features by using non-linear predictors 
for those subpopulations (clusters) in which the interactions between features are 
important.   
 Tops/R addresses the heterogeneity across time horizons by constructing different 
predictions for different time horizons. 
 
Predictors and predictive clusters 
The distinction between discriminative and predictive features is useful both for 
understanding the working of ToPs/R and also for understanding the complex 
interactions between the different predictive features and their impact on survival 
probabilities. Discriminative features break down the entire population into smaller 
subpopulations (clusters). Because we use Cox Regression, Linear Regression and 
Logistic Regression as the basic learners, the most predictive features in a cluster are 
those whose coefficients have the largest magnitude (either positive or negative). Figure 
5 (which shows the entire Tree of Predictors for 3-year survival in the wait-list) presents 
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a good illustration of the point that different features are more predictive in different 
clusters.  In each cluster, we show the (index of the) three features that are most 
predictive of survival (for that time horizon) for that cluster ordered in terms of predictive 
importance.  Note that different features are important in different clusters. See also 
Figure 2(b) and the discussions in the Results section and in the Supplementary Materials. 
 
 The key idea of ToPs is to discover how to apply different predictors (predictive 
models) on different portions of the feature space (clusters) and hence to discover how to 
tune the overall prediction to the features of the patient for which the prediction is to be 
made.  Each of the predictors applied is constructed from one of a prescribed set of base 
learners (algorithms).  In principle, the prescribed set of base learners could be arbitrary, 
but for the purposes of this paper we restrict to a small family of familiar base learners: 
Cox Regression, Linear Regression and Logistic Regression; in addition to familiarity, 
this has the advantage of interpretability.  (Expanding the set of base learners would 
increase the accuracy of our predictions – but at the cost of interpretability; this 
represents a familiar trade-off.)  To construct a predictor from a base learner means to 
choose the parameters of the learner; for these learners this means choosing the 
coefficients of the regressor.  At each step of the recursive procedure, we jointly choose 
the base learner and the parameters of the learner in order to achieve the best fit on an 
appropriate portion of the data that we use for training.  (See Materials and Methods for a 
more complete description.) 
 It is important to understand what it means to apply different predictors on different 
clusters and why doing so yields improved predictions and is key for personalized 
medicine.  Two examples will illustrate this.   
 Suppose first that we have two distinct clusters 1C  and 2C  and that we apply 
Linear Regression as the base learner on both of these clusters.  In general, we 
will choose the coefficients of the linear regressor – the predictor – to best fit 
different portions of the data; hence, there will be at least one feature whose 
coefficient in the predictor for 1C  is different from its coefficient in the predictor 
for 2C .  This means that this feature will have different importance in the 
predictions for patients whose features lie in 1C  than for patients whose features 
lie in 2C .   
 Suppose instead that that we again have two distinct clusters 1C  and 2C  but that 
we apply Linear Regression as the base learner on 1C  but apply Logistic 
Regression as the base learner on 2C . By definition, Linear Regression produces a 
linear predictor, which implies that the various features do not interact with each 
other.  To the contrary, Logistic Regression produces a non-linear predictor, 
which implies that the various features do interact with each other.  (We can see 
similar contrasts with Cox Regression, which also produces a non-linear predictor 
in which the various features interact with each other – but in a way that is 
different from Logistic Regression.) 
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 In short: using different predictors on different clusters means that we allow different 
features to have different importance and/or to interact differently for different clusters of 
patients.  And because we make the choice of predictors endogenously and optimally, we 
are letting the data tell us which choices to make. 
 
Decision trees 
Although our method constructs trees of subsets of the feature space, it is very important 
to distinguish our method from familiar decision trees.  Both our method and decision 
trees use a feature to create each split and hence in both cases successive splits lead to 
clusters in which the features are more homogeneous than in the population as a whole.  
However, this is really the only similarity.  Decision trees split according to a feature, but 
they decide which split should be chosen according to which split leads to greater 
homogeneity in the labels – the outcomes.  Our method splits according to a feature, but 
it decides which split should be chosen according to which split leads to more accurate 
predictions.  In particular, a decision tree assigns a single prediction to each terminal 
node; our method assigns a single predictor to each decision node – but that single 
predictor may make a wide variety of predictions for the wide variety of patient features 
represented in that terminal node. See the Supplementary Materials for illustrative 
histograms.  
 
Survival analysis 
The existing clinical risk scores do not produce individual survival curves. Clinicians 
using these scores infer survival curves by clustering patients with similar scores and 
constructing Kaplan-Meier curves from the actual survival times for these clusters.  Our 
method produces individual survival curves by interpolating the predictions for 3 months, 
1 year, 3 years and 10 years.  Our approach can be viewed as providing a non-parametric 
survival model.  In terms of hazard functions, our method could be interpreted as forming 
clusters, assigning a model to each cluster, and then aggregating those models to 
construct a non-proportional hazard function.  In contrast to familiar approaches (24, 25) 
our approach learns which clusters to create, which models to assign and how to 
aggregate these models.  
 
 Cox Regression produces individual survival curves. However, because Cox 
Regression assumes that relative hazard rates are constant over time, the survival curves 
produced by Cox Regression for two different patients cannot cross: if the survival 
probability for patient 1 is greater than that of patient 2 at a time horizon of 3 months it 
will also be greater at every time horizon.  However, actual survival curves may cross.  
Our method allows for this is a virtue, reflecting the fact that the features and interactions 
that are most important for survival at 3 months are different from the features and 
interactions that are most important for survival at longer horizons. (See Figure 2.)  
 
LVADs 
Perhaps the most significant advance in heart failure technology has been the 
development of mechanical circulatory support devices, especially LVADs that can be 
surgically implanted and support or replace the function of the failing heart.  Patients who 
receive LVADs typically remain on LVADs until transplantation or death; a small 
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proportion of patients recover their heart function sufficiently that their LVAD can be 
explanted. First generation (pulsatile) LVADs were approved by the U.S. Food and Drug 
Administration in 1994.  However, use of LVADs only increased significantly in about 
2005 and became widespread in the U.S. and some other countries in 2009 with the 
development of second generation (non-pulsatile) LVADs (26-28).  Initially, LVADs 
were used largely as a bridging therapy, maintaining patients until they could receive a 
transplant.  After the landmark REMATCH trial in 2001 (29), it has become more 
common to use LVADs as destination therapy for patients with end-stage heart failure 
who are not eligible for Heart Transplantation (30, 31).  Approximately 25.0% of patients 
currently on wait lists in the U.S. now receive LVADs.  Therefore, there is a need to 
assess whether different risk prediction tools are required for this patient subpopulation. 
In this paper, we analyze the subgroup of patients who receive an LVAD, both with 
respect to survival in the wait-list and post-transplantation.  Our method achieves similar 
predictive accuracy for patients who received LVADs (both in the wait-list and post-
transplantation) and patients who did not; these predictions are again significantly more 
accurate than existing clinical scores and other machine learning methods. Because our 
methods are applicable both to patients who have received LVADs and those who have 
not, and because our methods predict both survival on the wait-list and survival post-
transplantation with significantly improved accuracy, our methods provide the potential 
for improved heart transplantation policy that could lead to improved clinical outcomes. 
  
Clinical support 
Our work provides support for clinical decision making in real time.  By using our user-
friendly website http://medianetlab.ee.ucla.edu/ToPs_TransplantSurvival and entering 
relevant features, the clinician can obtain immediate predictions for a specific patient, 
including survival on the wait-list, impact of an LVAD (if relevant), and benefit of 
transplantation (if relevant).  All of this can be done at the desk of the clinician or the 
bedside of the patient, in no more time than is currently required to access the clinical 
risk scores, and with much greater accuracy (and confidence). 
 
Risk scoring and usability 
Our analysis shows that our method provides significantly greater predictive power for 
survival while on the wait-list and post-transplantation. However, more research in actual 
practice is required. This success of our method in the setting of cardiac transplantation 
suggests it may have wide applicability and usability for risk prognosis and diagnosis for 
other medical conditions and diseases. Such wider applications may benefit from further 
refinements of our method. 
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MATERIALS AND METHODS 
 
Study Design 
We conducted our study using the United Network for Organ Sharing (UNOS) database 
of patients who were registered to undergo heart transplantation during the years from 
1985 to 2015 (available at https://www.unos.org/data/).  This provided a dataset of 
60,400 patients who received heart transplants and 36,329 patients who were on a wait 
list but did not receive heart transplants; we refer to the former as transplanted patients 
and to the latter as wait-listed patients. Of the 60,400 transplanted patients, 29,436 
patients (48.7%) were followed until death and the remaining 30,964 patients (51.3%) 
were either still alive or their exact survival time was not known (i.e., these patients were 
right-censored).  Of the 36,329 wait-listed patients, 18,584 patients (51.2%) were 
followed until death; the remaining 17,745 patients (48.8%) were either still alive or their 
exact survival time was not known (i.e., these patients were right-censored).  
  
 Patients in the dataset are described by a total of 504 clinical features.  Of these, 334 
features pertain to (potential) recipients, 150 features pertain to donors and 20 features 
pertain to donor-recipient compatibility. We discarded 12 features that can be obtained 
only after transplantation and so cannot be used for prediction before transplantation, and 
439 features for which more than 10.0% of the information was missing.   After 
discarding these, we were left with 33 recipient features, 14 donor features and 6 donor-
recipient compatibility features – a total of 53 features (See Supplementary Materials.) 
Categorical binary features (e.g. Male/Female) are represented as 0, 1; categorical non-
binary features are converted to binary features (e.g. blood type A/not-A); other features 
are represented as real numbers.  For patients and features for which values are missing, 
we use standard imputation methods. More specifically, we conduct 10 multiple 
imputations using Multiple Imputation by Chained Equations (MICE) as in (32) and 
represent the performance of the various algorithms by showing both means and 
confidence intervals. Furthermore, we use the Sequential Correlated Feature Selection 
(SCFS) procedure of (33) to compute a relevance score for each feature.  These scores 
depend on the task at hand: the relevance scores for survival on the waiting list are 
different for different time horizons, and the relevance scores for survival on the waiting 
list are different from the relevance scores for survival after transplantation (for various 
time horizons). The Supplementary Materials provides a complete list of all 53 features, 
the relevance scores for each prediction we make, and the subset of features actually used 
for that prediction.   
 To develop and test our models we used 5-fold cross validation.  We randomly 
separated both the wait list and post-transplantation data sets into 5 folds.  In each of 5 
iterations, 4 of the folds (80.0% of the data) were used for development of the models and 
the remaining fold (20.0% of the data) was put aside for evaluating performance.  
 
Clinical risk scores and survival analysis 
Three predictors for survival times on the wait list are in widespread use in clinical 
practice: the Heart Failure Survival Score (HFSS), the Seattle Heart Failure Model 
(SHFM) and Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) (18, 34, 
35).  Similarly, three predictors for survival times after transplant are in widespread use 
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in clinical practice: the Donor Risk Index (DRI), the Risk-Stratification Score (RSS), and 
the Index for Mortality Prediction After Cardiac Transplantation (IMPACT) (19, 22, 36).  
All of these predictors compute an overall risk score (a weighted sum of scores of 
individual features). The numerical score assigned to a particular patient is only 
meaningful in comparison with the numerical scores assigned to other patients: patients 
with higher risk scores are viewed as more likely to die/less likely to survive for any 
given time horizon.  
  
Performance metrics and comparisons 
The performance of any risk scores can be assessed in terms of the Receiver Operating 
Characteristic (ROC) curve that plots the True Positive Rate (TPR) (sensitivity) against 
the False Positive Rate (FPR) (1 – specificity). A summary performance statistic is the 
Area Under the ROC Curve (AUC). We report the performance (AUC for survival on the 
wait list and for survival post-transplantation at the time horizons of 3 months, 1 year, 3 
years and 10 years) of ToPs/R, of three familiar regression methods, and of the relevant 
clinical risk scores.  We also compare with a number of state-of-the-art machine learning 
approaches. 
 
Implementation of ToPs 
Our approach uses a novel ensemble learning method that we call ToPs because it 
constructs Trees of Predictors.   The implementation we use here uses as its base learners 
(algorithms) three familiar regression algorithms – Cox Regression, Linear Regression 
and Logistic Regression – so we use the acronym ToPs/R.  In fact, we could use any 
collection of base learners, and a larger or more sophisticated collection of base learners 
would lead to improved predictive accuracy.  The choice of base learners made here was 
motivated by their familiarity and widespread use and because it lends itself more readily 
to interpretation of the clusters that are discovered.  This is just another example of the 
well-known trade-off between accuracy and interpretability.  
 
Model development: Base learners 
As discussed in the Introduction, the current clinical models compute risk scores as 
weighted linear combinations of scores of various features.  However, as Tables 1 and 2 
show, the current clinical models do not perform well.  Because the various clinical 
models do not optimize the choices of features and weights used and compute a single 
risk score to be used for all time horizons, there is room for significant improvement by 
carrying out a Linear Regression that fits the best linear regressor for each time horizon 
separately.  As Tables 1 and 2 show, this approach leads to a substantial improvement 
over all of the clinical risk scores.  However, by its very nature, Linear Regression does 
not capture interactions between features.  Both Cox Regression and Logistic Regression, 
do capture (some) interactions between features.  As Tables 1 and 2 show, however, 
although Logistic Regression does perform better than Linear Regression for some 
predictions, the improvement is small, and Cox Regression performs worse than either 
Linear Regression or Logistic Regression.  (Recall that Cox Regression assumes that 
hazards are proportional and constant over time; as noted in the Discussion, for at least 
some patients this is not true.)  
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Model development: Personalization and Clusters 
As discussed in the Introduction, because patient (and patient-donor) features are very 
heterogeneous, the predictive models to be used should be personalized to (the features of) 
a patient.  We accomplish this personalization by using the data to identify predictive 
clusters – clusters of patients for whom predictions can best be made by using some 
specific learner, trained in some specific way (i.e. with coefficients fitted to some specific 
training set) – and then combining the predictions obtained over the clusters that contain 
the array of features of the particular patient for whom we need a prediction.  This 
approach allows us to construct a complex predictor from simple learners.   
 
 A potential problem with any such construction is that the predictor becomes too 
complex and hence overfits.  One way to control model complexity is to append a term 
that penalizes for complexity – but then the magnitude of the penalty term would become 
a parameter of the model.  Instead, our approach controls model complexity 
automatically by training learners on one part of the development set and then validating 
on a different part of the development set.  We give an outline below; further details, 
including the pseudocode for the algorithm, can be found in the Supplementary Materials. 
 
Model development: Tree of predictors  
Our method recursively splits the space X  (of patient features or patient-donor-
compatibility features) into disjoint subsets (clusters) and, for each cluster, creates a 
specific predictor by training a learner from the given base class R  of learners (Cox 
Regression, Linear Regression, Logistic Regression) using the development set.  This 
creates a tree of predictors: a tree T  of clusters (nodes) of the feature space X  together 
with a predictor Ch  associated to each cluster C  in the tree.  The overall prediction for a 
particular patient (or patient-donor pair) having a specific array of features is formed by 
finding the unique terminal node (cluster) of the tree to which that array of features 
belongs and the unique path through the tree from the initial node to this terminal node 
(this is precisely the set of clusters to which the patient belongs) and forming a weighted 
average of the predictions of the predictors along this path, with weights determined (for 
the particular path) optimally by linear regression. 
 
 The construction of the optimal tree of predictors is recursive; at each stage it builds 
on the tree previously constructed.  We initialize the construction (Stage 0) by defining 
the initial node of the tree to be the entire space X  of features. To determine the 
predictor Xh  to be assigned to the initial node, we train each of the learners in R  globally; 
that is, for each learner we find the coefficients that create the predictor that best fits the 
development set.  Among these predictors, we set Xh  to be the one that yields the overall 
best fit.  Having done this we have built a (trivial) tree of predictors (i.e., a single node 
and predictor).  At each successive stage 1n  we begin with the tree nT  of predictors 
constructed in previous stages.  For each terminal node C  of nT  we proceed as follows.  
Fix a feature i  and a threshold i .  (If necessary, we discretize all continuous features.) 
Define 
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{ : },     { : }i i i iC x C x C x C x         
 
Fix learners ,L L R    and nodes , nA A T    that weakly precede ,C C
  , respectively.  
Train L  on A  (i.e., find the coefficients of L  that best fit the portion of the 
development data with features in A ) and train L  on A ; call the resulting predictors 
,h h  .  Using  h  on C  and h  on C  yields a predictor h h   on C C C   . 
Among all choices of the feature i , the threshold i , the learners ,L L   and the training 
sets ,A A  , find those that maximize the AUC of h h   on C . (See the precise details 
in the Supplementary Materials.) This defines a split of C C C    and predictors 
associated with the sets ,C C  . If no further improvement is possible, we stop splitting. 
It can be shown that the process stops after some finite number of stages. 
 
 Note that at each stage the construction jointly chooses the feature, the threshold, the 
learner and the training set to optimize the gain in predictive power and the construction 
stops when no further gain is possible; the end result of the process is the optimal tree of 
predictors.   
 
 To determine the prediction for a patient having the array x of features, we find the 
set   of all nodes in the tree to which the array of features x  belongs; this is the unique 
path from the initial node X  to the unique terminal node to which x  belongs.  The 
overall prediction for x  is the weighted average  
 
( ) ( , ) ( )C
C
H x w C h x

    
 
where the weights ( , )w C   are determined optimally by linear regression. (See 
Supplementary Materials for precise details.) 
  
 A typical optimal tree of predictors is shown in Figure 5.  (For other prediction trees, 
see the Supplementary Materials.)  Figure 5 shows the feature and threshold used to 
create each split.  Within each cluster, it shows the learner used to create the predictor for 
that node, the total number of patients within that cluster and the index of the three most 
relevant features for that cluster.  (The list of relevant features is shown in lower part of 
Figure 5.)  Note that, as is typical of our method, the tree constructed is not very deep – 
the recursive process of construction stops fairly quickly because no further improvement 
is possible. (See Supplementary Materials for some additional trees.)  Consequently, only 
a few of these clusters are small. 
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CONCLUSION 
We offer a new method for personalized risk prediction using a novel machine learning 
technique.  Our method is explicitly designed to address the heterogeneity of the 
patients/donor populations and the fact that the effect of particular features on survival is 
different for different subpopulations. Moreover, our method is also designed to capture 
the interaction between features and the differences in interactions across different 
subpopulations. Finally, our method captures the different effects of features and 
interactions between features for different time horizons. Our method outperforms 
existing clinical scores and state-of-the-art machine learning methods and is easily 
interpretable and applicable by clinicians. The present study has important clinical 
implications for the practice and policy of heart transplantation. The general methodology 
developed here has wide applicability to the construction of personalized risk scores in 
other medical domains. 
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Table 3. ToPs/R improvement percentage over other methods for survival prediction in wait-list 
and post-transplantation  
 
- Figures 
Figure 1. (a) ROC curve for wait-list survival prediction, (b) ROC curve for post-transplantation 
survival prediction 
Figure 2. (a) Informative features for each cluster for 3-month wait-list survival prediction, (b) 
3-year wait-list survival prediction, (c) for 3-month post-transplantation survival prediction, (d) 
for 3-year post-transplantation survival prediction, (e) for wait-list survival across the time 
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Figure 4. (a) Wait-list survival curves for LVAD / LVAD eligible / Entire patients in 2005-2009 
and 2010-2015, (b) Post-transplantation survival curves for LVAD / LVAD eligible / Entire 
patients in 2005-2009 and 2010-2015 
Figure 5. Tree of predictors for 3-year survival in wait-list 
Algorithms Risk Score AUC (95% Confidence Bound) 3-month survival 1-year survival 3-year survival 10-year survival 
Our Model ToPs/R 0.847 (0.846 – 0.848) 
0.813 
(0.812 – 0.814) 
0.792 
(0.791 – 0.793) 
0.760 
(0.759 – 0.761) 
Existing Clinical  
Risk Scores 
HFSS 0.618 (0.617 – 0.619) 
0.624 
(0.623 – 0.625) 
0.621 
(0.620 – 0.622) 
0.615 
(0.614 – 0.616) 
MAGGIC 0.630 (0.629 - 0.631) 
0.641 
(0.640 – 0.642) 
0.643 
(0.642 – 0.644) 
0.629 
(0.628 – 0.630) 
SHFM 0.601 (0.599 – 0.602) 
0.603 
(0.602 – 0.604) 
0.604 
(0.603 – 0.605) 
0.610 
(0.609 – 0.611) 
Our Regressions 
Cox Regression 0.716 (0.715 – 0.718) 
0.708 
(0.707 – 0.708) 
0.672 
(0.671 – 0.673) 
0.587 
(0.586 – 0.588) 
Linear Regression 0.736 (0.736 – 0.737) 
0.734 
(0.733 – 0.736) 
0.719 
(0.718 – 0.720) 
0.662 
(0.661 – 0.663) 
Logistic Regression 0.760 (0.758 – 0.761) 
0.731 
(0.729 – 0.732) 
0.715 
(0.713 – 0.716) 
0.705 
(0.704 – 0.706) 
Machine Learning 
Benchmarks 
(Boosting-based) 
AdaBoost 0.818 (0.816 – 0.820) 
0.787 
(0.785 – 0.788) 
0.777 
(0.776 – 0.779) 
0.745 
(0.744 – 0.746) 
Deep Boost 0.821 (0.820 – 0.822) 
0.790 
(0.789 – 0.791) 
0.773 
(0.772 – 0.774) 
0.739 
(0.738 – 0.740) 
Logit Boost 0.745 (0.744 – 0.746) 
0.737 
(0.736 – 0.739) 
0.723 
(0.722 – 0.724) 
0.678 
(0.677 – 0.679) 
XGBoost 0.824 (0.823 – 0.825) 
0.794 
(0.792 – 0.795) 
0.778 
(0.777 – 0.779) 
0.746 
(0.744 – 0.747) 
Machine Learning 
Benchmarks 
(Tree-based) 
Decision Tree 0.819 (0.818 – 0.820) 
0.783 
(0.782 – 0.785) 
0.764 
(0.763 – 0.766) 
0.744 
(0.743 – 0.745) 
Random Forest 0.824 (0.823 – 0.826) 
0.793 
(0.791 – 0.794) 
0.774 
(0.773 – 0.776) 
0.728 
(0.727 – 0.729) 
Machine Learning 
Benchmarks 
(Others) 
LASSO 0.759 (0.758 – 0.760) 
0.733 
(0.732 – 0.734) 
0.722 
(0.721 – 0.724) 
0.686 
(0.684 – 0.687) 
Neural Networks 0.788 (0.786 – 0.789) 
0.781 
(0.780 – 0.782) 
0.770 
(0.769 – 0.771) 
0.741 
(0.740 – 0.743) 
 
Table 1. Comparison of AUC values among ToPs/R, existing clinical risk scores, basic regression methods, and machine learning 
benchmarks for survival prediction in wait-list (3-month, 1-year, 3-year, and 10-year). (p-values < 0.01) 
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Algorithms Risk Score AUC (95% Confidence Bound) 3-month survival 1-year survival 3-year survival 10-year survival 
Our Model ToPs/R 0.676 (0.675 – 0.678) 
0.664 
(0.663 – 0.665) 
0.634 
(0.633 – 0.635) 
0.636 
(0.635 – 0.637) 
Existing Clinical  
Risk Scores 
DRI 0.572 (0.571 – 0.573) 
0.562 
(0.561 – 0.563) 
0.551 
(0.550 – 0.552) 
0.550 
(0.549 – 0.551) 
IMPACT 0.581 (0.580 – 0.582) 
0.570 
(0.569 – 0.571) 
0.552 
(0.551 – 0.554) 
0.531 
(0.530 – 0.532) 
RSS 0.563 (0.562 – 0.564) 
0.564 
(0.553 – 0.565) 
0.558 
(0.557 – 0.559) 
0.567 
(0.566 – 0.568) 
Our Regressions 
Cox Regression 0.607 (0.606 – 0.608) 
0.596 
(0.595 – 0.597) 
0.573 
(0.572 – 0.574) 
0.562 
 (0.561 – 0.563) 
Linear Regression 0.641 (0.640 – 0.642) 
0.623 
(0.622 – 0.624) 
0.603 
(0.602 – 0.605) 
0.616 
(0.614 – 0.617) 
Logistic Regression 0.638 (0.636 – 0.639) 
0.621 
(0.620 – 0.622) 
0.602 
(0.601 – 0.603) 
0.616 
(0.615 – 0.617) 
Machine Learning 
Benchmarks 
(Boosting-based) 
AdaBoost 0.651 (0.649 – 0.652) 
0.630 
(0.629 – 0.631) 
0.603 
(0.602 – 0.605) 
0.616 
(0.614 – 0.617) 
Deep Boost 0.646 (0.645 – 0.648) 
0.635 
(0.634 – 0.636) 
0.610 
(0.609 – 0.611) 
0.613 
(0.612 – 0.615) 
Logit Boost 0.637 (0.636 – 0.638) 
0.622 
(0.621 – 0.623) 
0.596 
(0.595 – 0.597) 
0.613 
(0.612 – 0.614) 
XGBoost 0.618 (0.617 – 0.6200) 
0.608 
(0.607 – 0.609) 
0.588 
(0.587 – 0.589) 
0.615 
(0.614 – 0.616) 
Machine Learning 
Benchmarks 
(Tree-based) 
Decision Tree 0.630 (0.629 – 0.631) 
0.611 
(0.610 – 0.612) 
0.590 
(0.588 – 0.591) 
0.599 
(0.598 – 0.600) 
Random Forest 0.653 (0.652 – 0.654) 
0.641 
(0.640 – 0.642) 
0.611 
(0.610 – 0.613) 
0.619 
(0.618 – 0.621) 
Machine Learning 
Benchmarks 
(Others) 
LASSO 0.627 (0.626 – 0.629) 
0.615 
(0.614 – 0.616) 
0.594 
(0.593 – 0.595) 
0.616 
(0.615 – 0.617) 
Neural Networks 0.641 (0.640 – 0.643) 
0.638 
(0.637 – 0.639) 
0.610 
(0.609 – 0.611) 
0.615 
(0.613 – 0.616) 
 
Table 2. Comparison of AUC values among ToPs/R, existing clinical risk scores, basic regression methods, and machine learning 
benchmarks for survival prediction post-transplantation (3-month, 1-year, 3-year, and 10-year). (p-values < 0.01) 
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 Algorithms Risk Score ToPs/R % improvement 3-month survival 1-year survival 3-year survival 10-year survival 
Survival 
prediction in 
Wait-list 
Our Model ToPs/R     
Existing Clinical  
Risk Scores 
HFSS 59.9% 50.2% 45.1% 37.6% 
MAGGIC 58.6% 47.9% 41.8% 35.2% 
SHFM 61.6% 52.9% 47.5% 38.4% 
Our Regressions 
Cox Regression 46.0% 36.1% 36.6% 41.9% 
Linear Regression 42.0% 29.6% 26.1% 28.9% 
Logistic Regression 36.3% 30.6% 27.1% 18.6% 
Machine 
Learning 
Benchmarks 
Boosting-
based 
AdaBoost 15.8% 12.4% 6.6% 5.7% 
Deep Boost 14.3% 11.0% 8.4% 7.9% 
Logit Boost 39.9% 28.9% 24.9% 25.5% 
XGBoost 13.0% 9.5% 6.4% 5.5% 
Tree-based Decision Tree 15.4% 13.7% 11.8% 6.1% Random Forest 12.8% 9.8% 7.8% 11.6% 
Others 
LASSO 36.3% 29.8% 25.1% 23.5% 
Neural Networks 27.8% 14.5% 9.7% 7.1% 
Survival 
prediction in  
Post-
transplant 
Our Model ToPs/R     
Existing Clinical  
Risk Scores 
DRI 24.4% 23.3% 18.5% 19.2% 
IMPACT 22.8% 21.8% 18.2% 22.5% 
RSS 26.0% 22.8% 17.2% 15.9% 
Our Regressions 
Cox Regression 17.6% 16.8% 14.2% 16.9% 
Linear Regression 9.9% 10.7% 7.7% 5.4% 
Logistic Regression 10.7% 11.4% 7.9% 5.2% 
Machine 
Learning 
Benchmarks 
Boosting-
based 
AdaBoost 7.4% 9.1% 8.0% 4.9% 
Deep Boost 8.5% 7.9% 6.1% 5.9% 
Logit Boost 10.8% 11.1% 9.3% 6.0% 
XGBoost 15.2% 14.1% 11.2% 5.5% 
Tree-based Decision Tree 12.6% 13.6% 10.8% 9.3% Random Forest 6.7% 6.2% 5.8% 4.4% 
Others LASSO 13.1% 12.7% 9.7% 5.3% Neural Networks 9.8% 7.2% 6.1% 5.6% 
 
Table 3. ToPs/R improvement percentage over other methods for survival prediction in wait-list and post-transplantation  
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Figure 1 (a) 
 
Figure 1 (b) 
 
Figure 1. (a) ROC curve for wait-list survival prediction, (b) ROC curve for post-transplantation 
survival prediction 
 
 6 
Figure 2 (a) Figure 2 (b) 
Figure 2 (c) Figure 2 (d) 
Figure 2 (e) Figure 2 (f) 
 
Figure 2. (a) Informative features for each cluster for 3-month wait-list survival prediction, (b) 
3-year wait-list survival prediction, (c) for 3-month post-transplantation survival prediction, (d) 
for 3-year post-transplantation survival prediction, (e) for wait-list survival across the time 
horizon, (f) for wait-list survival across the time horizon 
 7 
 
Figure 3. Tree of predictors for 3-year post transplantation survival (End nodes shaded gray.  3 
most relevant features shown for each node.) 
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Figure 4 (a) 
 
Figure 4 (b) 
 
Figure 4. (a) Wait-list survival curves for LVAD / LVAD eligible / Entire patients in 2005-2009 
and 2010-2015, (b) Post-transplantation survival curves for LVAD / LVAD eligible / Entire 
patients in 2005-2009 and 2010-2015 
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Figure 5. Tree of predictors for 3-year survival in wait-list ((End nodes shaded gray. 3 most 
relevant features shown for each node.) 
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ADDITIONAL DISCUSSIONS 
Predictive features and discriminative features 
Our method successively splits the population into subpopulations by finding features that 
discriminate between subpopulations for which the best-fitting predictive models are different. A 
separate, tailored predictive model is then constructed for each given subpopulation using the 
features that are predictive of survival for that subpopulation. Discriminative and predictive 
features need not be the same. The following analogy may illustrate the distinction between 
discrimination and prediction. Assume that we have a population of patients for whom we want 
to perform accurate diagnosis for some underlying disease, and assume that each patient can 
undergo one of two possible diagnostic tests: a blood test and a genetic test. Suppose we know 
that for a left-handed patient, the genetic test is more accurate than the blood test, whereas for a 
right-handed patient, the blood test has a higher diagnostic accuracy. In this hypothetical 
scenario, it is optimal to split the population into a left-handed subpopulation, for which a 
genetic test is recommended, and a right-handed subpopulation, for which a blood test is 
recommended. In this example, handedness is a discriminative feature: it need not tell us 
anything about the true diagnosis in either subpopulation, but it informs us as to which 
diagnostic test should be selected for which patient. The diagnostic tests, which are analogous to 
predictive models, depend on different predictive features for the different subpopulations: for 
the left-handed subpopulation, the "predictive features" are genetic information, whereas for the 
right-handed subpopulation, the predictive features are hematologic information. In a very 
similar manner, ToPs uses discriminative features to determine the right predictive model for the 
right subpopulation, and uses the predictive features to cast a predictive model for every 
subpopulation. The identification of a feature as being discriminative or predictive (or both) is 
driven completely by the data. (As can be seen in the Supplementary Materials, BMI has 
substantial discriminatory power but little predictive power, ECMO has substantial predictive 
power but little discriminatory power, and Age has both substantial discriminatory power and 
substantial predictive power.) 
Complex models versus simple models  
As a general principle, complex models are better able to fit the data than are simple models, but 
complex models are more likely to suffer from over-fitting than are simple models.  Hence it 
may be better to prefer a simple model (e.g. Linear Regression) rather than a more complex 
model (e.g. Logistic Regression) when the data set is “small.”  In our setting, the entire data set is 
large but some clusters may be “small”; our method takes into account the size of the cluster and 
uses the data to decide how to resolve the tension between complexity and simplicity.   
 
  
  
 
 
Figure S1. Flow chart from heart failure to post heart transplantation 
  
 
Off-line Stage 0: Dividing the dataset ( D ) 
Input: Entire dataset D  
Divide D  into disjoint training set ( S ), the first validation set ( 1V ), the second validation set 
( 2V ) and testing set ( ) which satisfy 1 2D S V V      
Output: Training set S , validation sets 1V , 2V , and testing set   
Off-line Stage 1: Growing the Optimal Tree of Predictors  
Input: Feature space X , a set of algorithms  , training set S , the first validation set 1V    
First step: Initial tree of predictors ( , )XX h  where 1arg min ( ( ), )X Ah L A S V   
Recursive step: 
Input: Current tree of predictors ( ,{ })CT h  
For each terminal node C T  do 
     For a feature i  and a threshold i  do 
          Set ( ) { : },   ( ) { : }i i i i i iC x C x C x C x           Then,  
          * *
* * 1 1
( ) ( )
{ , , , } arg min ( , ( ( )) ( ( )))
i i
i i iC C
i h h L h h V C V C    
        
           where ( ( ) ),  ( ( ) )i ih C h C          
End for 
End for 
Stopping Criteria: 1 1 1( , ( )) min ( , ( ( )) ( ( )))C i iL h V C L h h V C V C         
Output: Locally optimal tree of predictors ( ,{ })CT h  
Off-line Stage 2: Weights Optimization on the Path  
Input: Locally optimal tree of predictors ( ,{ })CT h , the second validation set 
2V  
For each terminal node C and the corresponding path   from X to C  
     For each weight vector ( )Cw w ,  
     Define w C C
C
H w h

  , Then,   
      * * 2( ) ( ( , )) arg min ( , ( ))ww w C L H V C      
End for 
Output: Optimized weights *( )w   for each terminal node C  and corresponding path    
On-line Stage: Overall Predictor 
Input: Locally optimal tree of predictors ( ,{ })CT h , optimized weights 
*( )w  , and testing set    
Given a feature vector ,x   
Find the unique path ( )x  from X  to terminal node containing ;x  
Then, *
( )
( ) ( , ) ( )C
C x
H x w C h x

    
Output: The final prediction ( )H x   
 
Figure S2. Pseudo-codes of ToPs/R 
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Figure S3. Tree of Predictors for the survival in wait-list (3-month) discovered by ToPs/R. 
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Figure S4. Tree of Predictors for the survival in wait-list (3-year) discovered by ToPs/R 
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Figure S5. Tree of Predictors for the post-transplantation survival (3-month) discovered by 
ToPs/R 
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Figure S6. Histograms for predictions in 6 clusters of tree of predictors for the survival in wait-
list (3-year) 
 
  
 
HFSS SHFM MAGGIC 
No Feature Name Relevance 
Score 
No Feature Name Relevance 
Score 
No Feature Name Relevance 
Score 
1 LVEF (%) 0.043 1 Recipient Age (years) 0.528 1 EF (%) 0.043 
2 
Mean Blood Pressure 
(mmHg) 0.171 2 Recipient Gender 0.226 2 Recipient Age (Year) 0.528 
3 pkVO2 (mg/dL) 0.098 3 
NYHA Functional 
Classification 0.173 3 
Systolic Blood 
Pressure 0.171 
4 Serum Sodium (mmol/L)  4 EF (%) 0.043 4 BMI 0.361 
5 Ischemic Cardiomyopathy 0.213 5 Etiology (Ischemic) 0.213 5 Creatinine (mmol/L) 0.182 
6 
Intraventricular 
Conduction Delay (ms)  6 
Systolic Blood Pressure 
(mmHg) 0.171 6 NYHA Class 0.173 
7 Resting Heart Rate (bpm)  7 ACE inhibitor 0.558 7 Recipient Gender 0.226 
   8 Diuretic (mg/day)  8 Current Smoker  
   9 Recipient Weight (kg) 0.123 9 Diabetic 0.595 
   10 Sodium (mEq/L)  10 Diagnosis of COPD  
   11 Hemoglobin (g/dL)  11 
First Diagnosis of 
Heart Failure  
   12 Lymphocytes (%)  12 Not on Beta Blocker 0.151 
   13 Uric Acid (mg/dL)  13 Not on ACEI/ARB 0.558 
   14 Cholesterol (mg/dL)     
Table S1. Features used in existing medical scores for survival in wait-list with relevance scores (HFSS, SHFM, MAGGIC) 
 
  
 
DRI RSS IMPACT 
No Feature Name Relevance 
Score 
No Feature Name Relevance 
Score 
No Feature Name Relevance 
Score 
1 Ischemic Time (hours) 0.494 1 Recipient Age (years) 0.348 1 Recipient Age (years) 0.348 
2 Donor Age (years) 1.000 2 Previous Cardiac Surgery 0.534 2 
Total Bilirubin 
(mg/dL) 0.023 
3 Recipient Race 0.017 3 
Etiology (Congenital / 
Amyloidosis)  3 Creatinine (mg/dL) 0.219 
4 Donor Race 0.013 4 Diabetes complicated by CVA 0.874 4 
Dialysis between 
listing and transplant 0.374 
5 BUN (mg/dL) 0.127 5 eGFR (mL/minute)   5 Recipient Gender  0.049 
6 Creatinine (mg/dL) 0.219 6 Total Bilirubin (mg/dL) 0.023 6 
Total Bilirubin 
(mg/dL) 0.023 
   7 
Acuity (Intubated / 
Hospitalized)  7 Heart Failure Etiology   
   8 RVAD only Support  0.093 8 Infection 0.281 
   9 ECMO Support 0.385 9 IABP Support 0.285 
   10 Extracorporeal LVAD Support 0.093 10 
Mechanical Ventilator 
Support 0.362 
   11 Total Artificial Heart Support 0.04 11 Recipient Race 0.017 
   12 Paracorporeal LVAD Support 0.093    
   13 Donor HEP C 0.392    
   14 Insulin Dependent Donor 0.06    
   15 Donor Age (years) 1.000    
   16 Ischemic Time (hours) 0.494    
   17 Donor Gender 0.199    
   18 Recipient Gender 0.049    
 
Table S2. Features used in existing medical scores for survival post-transplantation with relevance scores (DRI, RSS, IMPACT) 
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Recipient features Donor features Donor/Recipient Compatibility features 
No Feature Name No Feature Name No Feature Name No Feature Name 
1 Age (years) 19 Blood Type AB 1 Donor Age (years) 1 ABO Compatibility 
2 Gender 20 Dialysis 2 Donor Gender 2 Ischemic Time (hours) 
3 Height (cm) 21 IABP 3 Donor Height (cm) 3 HLA Mismatch 
4 Weight (kg) 22 Days in State 1 (days) 4 Donor Weight (kg) 4 A Mismatch 
5 Diabetes  23 Days in State 1A (days) 5 Donor Blood Type A 5 B Mismatch 
6 Infection  24 Days in State 2 (days) 6 Donor Blood Type B 6 DR Mismatch 
7 Transfusion  25 Days in State 1B (days) 7 Donor Blood Type O   
8 Previous Transplant 26 BMI (kg/mଶ) 8 Donor Blood Type AB   
9 # of Previous Transplant 27 LVAD Assist 9 HEP C Antigen   
10 Ventilator Assist 28 Total Artificial Heart 10 Donor Diabetes   
11 ECMO Assist 29 Inotropic 11 Donor BMI (kg/mଶ)   
12 Circulatory Support 30 EF (%) 12 Donor Infection   
13 Creatinine (mg/dL) 31 pkVO2 (mg/dL) 13 Bilirubin (mg/dL)   
14 Bilirubin (mg/dL) 32 ACE inhibitor 14 Creatinine (mg/dL)   
15 PRA (%) 33 Beta Blocker     
16 Blood Type A       
17 Blood Type B       
18 Blood Type O       
Table S3. Features used in ToPs 
  
  
 
Survival in Wait-list Survival after Transplant 
No Feature Relevance Score No Feature Relevance Score 
1 'Previous Transplant' 1.000 1 Donor Age 1.000 
2 'Days in State 1' 0.835 2 Diabetes 0.874 
3 '# of Previous Transplant' 0.799 3 BMI 0.700 
4 'Days in State 1B' 0.728 4 Days in State 1A 0.682 
5 Circulatory Support 0.717 5 Donor BMI 0.602 
6 'IABP' 0.696 6 Inotropic 0.565 
7 'Diabetes' 0.595 7 Donor Infection 0.545 
8 'Blood Type O' 0.590 8 Days in State 1B 0.544 
9 'Days in State 1A' 0.582 9 Previous Transplant 0.534 
10 ACE-inhibitor 0.558 10 Days in State 1 0.526 
11 'ECMO Assist' 0.556 11 Donor Creatinine 0.502 
12 'Days in State 2' 0.545 12 Ischemic Time 0.494 
13 'Age' 0.528 13 # of Previous Transplant 0.427 
14 'Ventilator Assist' 0.501 14 PRA 0.394 
15 Infection 0.405 15 HEP C Antigen 0.392 
16 'BMI' 0.361 16 ECMO Assist 0.385 
17 PRA 0.248 17 Dialysis 0.374 
18 'Gender' 0.226 18 Ventilator Assist 0.362 
19 Transfusion 0.189 19 Age 0.348 
20 'Creatinine' 0.182 20 Days in State 2 0.346 
21 'LVAD Assist' 0.174 21 Donor Height 0.287 
22 Beta Blocker 0.151 22 Transfusion 0.285 
23 Dialysis 0.143 23 IABP 0.285 
24 Total Artificial Heart 0.129 24 Infection 0.281 
25 Weight 0.123 25 Vent Support 0.27 
26 Inotropic 0.121 26 Blood Type A 0.239 
27 pkVO2 0.098 27 Height 0.231 
28 EF 0.043 28 HLA Mismatch 0.23 
29 'Blood Type AB' 0.015 29 Creatinine 0.219 
30 Bilirubin 0.012 30 DR Mismatch 0.21 
31 'Blood Type B' 0.009 31 Blood Type O 0.206 
32 'Height' 0.004 32 Distance 0.204 
33 'Blood Type A' 0.000 33 EF(%) 0.199 
   34 Donor Gender 0.199 
   35 Donor Blood Type A 0.177 
   36 A Mismatch 0.157 
   37 Donor Blood Type O 0.149 
   38 pkVO2 0.132 
   39 Weight 0.102 
   40 ACE inhibitor 0.094 
   41 LVAD Assist 0.093 
   42 B Mismatch 0.084 
   43 Donor Diabetes 0.06 
   44 Gender 0.049 
   45 Blood Type AB 0.042 
   46 Total Artificial Heart 0.04 
   47 Donor Blood Type AB 0.034 
   48 Bilirubin 0.023 
   49 Blood Type B 0.021 
   50 ABO_Compatible 0.016 
   51 Donor Blood Type B 0.015 
   52 Donor Bilirubin 0.012 
   53 Donor Weight 0.000 
Table S4. Feature used in ToPs sorted by normalized relevance score. (Features selected by 
CFSS are represented in gray.)  
  
 
No Abbreviation Meaning 
1 ACE Angiotensin-converting Enzyme 
2 ACEI Angiotensin-converting Enzyme Inhibitor 
3 ARB Angiotensin Receptor Blocker 
4 AUC Area Under the Curve 
5 BMI Body Mass Index 
6 BNP B-type Natriuretic Peptide 
7 BUN Blood Urea Nitrogen 
8 COPD chronic obstructive pulmonary disease 
9 CVA Cerebrovascular Accident 
10 DRI Donor Risk Index 
11 ECMO Extracorporeal Membrane Oxygenation 
12 EF Ejection Fraction 
13 eGFR Estimated Glomerular Filtration Rate 
14 HEP Hepatitis 
15 HFSS Heart Failure Survival Score 
16 HLA Human leukocyte antigen 
17 IABP Intra-Aortic Balloon Pump 
18 IMPACT Index for Mortality Prediction After Cardiac Transplantation 
19 LVAD Left Ventricular Assist Device 
20 LVEF Left Ventricular Ejection Fraction 
21 MAGGIC Meta-Analysis Global Group in Chronic Heart Failure 
22 NYHA New York Heart Association 
23 pkVO2 Peak Oxygen Consumption by Cardiopulmonary Exercise Testing 
24 PRA Panel Reactive Antibody 
25 RSS Recipient Stratification Score 
26 RVAD Right Ventricular Assist Device 
27 VAD Ventricular Assist Device 
Table S5. Abbreviations 
